EMJ Rheumatology 8.2 2021

Christopher Griffiths, Georg Schett, and Stefan Siebert presented a satellite symposium on the role of the IL-23 pathway in PsA: “The Launching Pad: Exploring the Potential of the IL-23 Pathway in PsA.” The experts discussed PsA pathogenesis, the most recent developments in the treatment of the disease, and the potential of IL-23 targeting to alleviate symptoms. The session included a panel discussion addressing a variety of engaging questions on different aspects of PsA, including symptom clearance and drug withdrawal. The panel of experts concluded the session by emphasising the importance of early diagnosis, patient lifestyle, and appropriate drug prescription to effectively manage PsA.